Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Rhea-AI Summary
Checkpoint Therapeutics (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. James Oliviero, the company's President and CEO, will deliver a corporate overview on September 10, 2024, at 10:00 a.m. ET.
The presentation will be accessible via webcast on Checkpoint's investor relations website for approximately 30 days following the event. Additionally, the company will engage in both in-person and virtual one-on-one meetings during the conference, providing an opportunity for investors to gain deeper insights into Checkpoint's operations and strategies.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CKPT declined 1.81%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 10:00 a.m. ET. The Company will also attend in-person and virtual one-on-one meetings during the conference.
A webcast of the presentation will be available on the News & Events page, located within the Investors section of Checkpoint’s website, https://ir.checkpointtx.com/event-calendar/default.aspx, for approximately 30 days after the meeting.
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential differentiated anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cSCC. Checkpoint is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (“EGFR”) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Checkpoint is headquartered in Waltham, MA and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.checkpointtx.com.
Company Contact:
Jaclyn Jaffe
Checkpoint Therapeutics, Inc.
(781) 652-4500
ir@checkpointtx.com
Investor Relations Contact:
Ashley R. Robinson
Managing Director, LifeSci Advisors, LLC
(617) 430-7577
arr@lifesciadvisors.com
Media Relations Contact:
Katie Kennedy
Gregory FCA
610-731-1045
Checkpoint@gregoryfca.com
FAQ
When is Checkpoint Therapeutics (CKPT) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Checkpoint Therapeutics (CKPT) at the investment conference?
Where can I watch the webcast of Checkpoint Therapeutics' (CKPT) presentation?
Will Checkpoint Therapeutics (CKPT) be conducting one-on-one meetings at the H.C. Wainwright conference?
